ABEO Long Call Strategy

ABEO (Abeona Therapeutics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

ABEO (Abeona Therapeutics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $325.7M, a trailing P/E of 4.89, a beta of 1.34 versus the broader market, a 52-week range of 4-7.54, average daily share volume of 1.2M, a public-listing history dating back to 1980, approximately 136 full-time employees. These structural characteristics shape how ABEO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.34 indicates ABEO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. The trailing P/E of 4.89 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.

What is a long call on ABEO?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current ABEO snapshot

As of May 15, 2026, spot at $5.53, ATM IV 115.20%, IV rank 29.35%, expected move 33.03%. The long call on ABEO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on ABEO specifically: ABEO IV at 115.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a ABEO long call, with a market-implied 1-standard-deviation move of approximately 33.03% (roughly $1.83 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABEO expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABEO should anchor to the underlying notional of $5.53 per share and to the trader's directional view on ABEO stock.

ABEO long call setup

The ABEO long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABEO near $5.53, the first option leg uses a $5.53 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABEO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABEO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$5.53N/A

ABEO long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

ABEO long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on ABEO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on ABEO

Long calls on ABEO express a bullish thesis with defined risk; traders use them ahead of ABEO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

ABEO thesis for this long call

The market-implied 1-standard-deviation range for ABEO extends from approximately $3.70 on the downside to $7.36 on the upside. A ABEO long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ABEO IV rank near 29.35% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ABEO at 115.20%. As a Healthcare name, ABEO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABEO-specific events.

ABEO long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABEO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABEO alongside the broader basket even when ABEO-specific fundamentals are unchanged. Long-premium structures like a long call on ABEO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ABEO chain quotes before placing a trade.

Frequently asked questions

What is a long call on ABEO?
A long call on ABEO is the long call strategy applied to ABEO (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ABEO stock trading near $5.53, the strikes shown on this page are snapped to the nearest listed ABEO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ABEO long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ABEO long call priced from the end-of-day chain at a 30-day expiry (ATM IV 115.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ABEO long call?
The breakeven for the ABEO long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABEO market-implied 1-standard-deviation expected move is approximately 33.03%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on ABEO?
Long calls on ABEO express a bullish thesis with defined risk; traders use them ahead of ABEO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current ABEO implied volatility affect this long call?
ABEO ATM IV is at 115.20% with IV rank near 29.35%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related ABEO analysis